[6-K] NOVO NORDISK A S Current Report (Foreign Issuer)
Novo Nordisk A/S held an Extraordinary General Meeting on 14 November 2025 to refresh its Board of Directors. Helge Lund, Henrik Poulsen and five other members stepped down. Shareholders elected Lars Rebien Sørensen as chair and Cees de Jong as vice chair, with Britt Meelby Jensen and Stephan Engels joining as members.
All elections run until the next Annual General Meeting on 26 March 2026. Following the meeting, committee roles were set: Sørensen will chair the People and Governance Committee; de Jong will chair the Remuneration Committee and serve on Audit; Engels will chair Audit and sit on Remuneration and People and Governance; and Kasim Kutay will chair the Research & Development Committee.
- None.
- None.
Insights
Board leadership reset with defined committee chairs; neutral impact.
The company completed a leadership transition at the board level, appointing Lars Rebien Sørensen as chair and Cees de Jong as vice chair. Committee leadership is clearly allocated: Audit to Stephan Engels, Remuneration to de Jong, and People & Governance to Sørensen, with Kasim Kutay chairing R&D. This clarifies oversight responsibilities.
Such governance changes are strategic but administrative in nature. The filing does not tie these appointments to operating targets or financial guidance. The impact on operations will depend on board-management priorities disclosed in future reports.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 14, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 14 November 2025 - Today, Novo Nordisk A/S held its Extraordinary General Meeting, which was convened to elect new members of the Board of Directors.
At the Extraordinary General Meeting, Helge Lund (chair), Henrik Poulsen (vice chair) and the Board members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay stepped down from the Board of Directors.
Resolutions adopted at the Extraordinary General Meeting
Elections
• Election of Lars Rebien Sørensen as chair of the Board of Directors.
• Election of Cees de Jong as vice chair of the Board of Directors.
• Election of Britt Meelby Jensen and Stephan Engels as members of the Board of Directors
All elections are for the period until the next Annual General Meeting, on 26 March 2026.
At the Extraordinary General Meeting, Lars Rebien Sørensen, chair of the Board of Directors of the Novo Nordisk Foundation, said: “My mandate is very clear. I have two important tasks together with the Board: First, to support the CEO and the management in its transformation plans to regain its competitive leadership, and second, prepare the way for my successor. Let me also stress, that as the future chair I will attend to the interests of not only the Novo Nordisk Foundation but all shareholders of the company. I am looking forward to engaging with and having a dialogue with the minority shareholders to understand their views.”
Page 2 of 2
Composition of the Board of Directors and its committees
After the Extraordinary General Meeting, the Board of Directors appointed members of its committees.
The Board of Directors, including its committees, is now composed as follows:
• Lars Rebien Sørensen (chair of the Board and chair of the People and Governance Committee)
• Cees de Jong (vice chair of the Board, chair of the Remuneration Committee and member of the Audit Committee)
• Elisabeth Dahl Christensen (employee-elected board member and member of the Remuneration Committee)
• Stephan Engels (chair of the Audit Committee and member of the Remuneration Committee and People and Governance Committee)
• Liselotte Hyveled (employee-elected board member and member of the Research & Development Committee)
• Mette Bøjer Jensen (employee-elected board member and member of the Audit Committee)
• Britt Meelby Jensen (member of the Remuneration Committee and member of the Research & Development Committee)
• Kasim Kutay (chair of the Research & Development Committee)
• Thomas Rantzau (employee-elected board member and member of the People and Governance Committee)
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,500 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | ||
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
|
| Investors: | ||
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Max Ung +45 3077 6414 mxun@novonordisk.com |
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
|
Alex Bruce +45 34 44 26 13 axeu@novonordisk.com |
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 35 / 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: November 14, 2025 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |
FAQ
What did Novo Nordisk (NVO) decide at the Extraordinary General Meeting?
When do the newly elected Novo Nordisk directors’ terms end?
Which Novo Nordisk directors stepped down from the board?
Who chairs Novo Nordisk’s board committees after the EGM?
Which committees will Stephan Engels and Britt Meelby Jensen join?
Where are Novo Nordisk shares listed?
How large is Novo Nordisk’s global workforce and reach?
